Topics:

Diagnostic and Management Issues in Gallbladder Carcinoma

Diagnostic and Management Issues in Gallbladder Carcinoma

Carcinoma of the gallbladder is a rare malignancy, with an incidence rate in the United States of 2.2 to 4.4 per 100,000 persons. Its clinical presentation is nonspecific, and the majority of patients have advanced disease at presentation. The diagnosis is rarely made preoperatively. About 90% of gallbladder cancers are adenocarcinomas. Surgical treatment is curative for lesions localized to the mucosa and submucosa, but these represent only about 16% of all gallbladder carcinomas. The role of radical surgery with node dissection and liver resection is controversial. Chemotherapy and radiation therapy do not have a major role in the treatment of gallbladder carcinoma. The prognosis is very poor, with a 5-year survival rate of less than 5%.

Introduction

Carcinoma of the gallbladder is an uncommon gastrointestinal malignancy that has a very poor prognosis. Since the original description of this cancer by Maximilian de Stoll in 1777, studies have established a characteristic pattern of late diagnosis and ineffective treatment.

In this article, we review the clinical pathology of the tumor and current results of therapy.

Incidence

Carcinoma of the gallbladder ranks fifth in incidence of gastrointestinal carcinomas and represents about three-fourths of extrahepatic biliary tract carcinomas [1]. Data from the National Cancer Institute's Surveillance, Epidemiology and End-Results (SEER) Program showed that, of a total of 160,238 carcinomas diagnosed from 1973 to 1975, 750 (47%) were gallbladder carcinomas [2].

Piehler and Crichlow, in a 1978 review [3], reported 1,091 instances of gallbladder carcinoma found during 57,170 biliary tract operations during a 15-year period--a prevalence rate of 1.91%. This represented a 35% increase over the 1.41% rate reported by Strauch [4] in 1960. It is difficult to determine whether this increase is real or related to more accurate reporting, however. In the same review by Piehler and Crichlow,3 results of reports appearing since 1960 documented 303 patients with carcinoma of the gallbladder discovered in 55,543 autopsies--a prevalence rate of .55%.

The annual incidence of gallbladder carcinoma in the United States is 2.5 to 4.4 per 100,000 persons [5]. The incidence of this cancer has been estimated to be six times higher in Southwest American Indians than in non-Indian populations.

Carcinoma of the gallbladder is a disease of elderly women, with a female to male ratio of about 3.2 to 1. The mean age at diagnosis, from 29 series, was 65.2 years [3] When stratified by age, the incidence of gallbladder carcinoma was .3% in those under 50 years of age, 3.8% in those over 50 years old, and 8.8% in those older than 65 years of age [6].

According to the Roswell Park experience, diabetes mellitus is present in 8.5% of patients with gallbladder carcinoma [7]. Reports on the subsequent incidence of a second primary cancer have varied from 5% to 20% [7-9].

Etiology

Although the etiology of gallbladder carcinoma is unknown, several epidemiologic risk factors have been proposed. Of these, cholelithiasis has been most frequently implicated as a possible risk factor.

Cholelithiasis

Cholelithiasis is found in 68% to 98% of patients with gallbladder cancer [7,8] Interestingly, the risk of gallbladder carcinoma increases directly with gallstone size [10] On the other hand, numerous autopsy series have reported an incidence of gallbladder carcinoma of only 1% to 3% among all patients with cholelithiasis [11]. Furthermore, in a series of 112 patients with asymptomatic gallstones followed for 10 to 25 years, there was not a single case of carcinoma [12]. Finally, about 25% of gallbladder carcinomas develop without documented cholelithiasis [3,4].

Thus, controversy exists over the interpretation of the association. However, gallstones and gallbladder cancer most likely share a common risk factor rather than a causal relationship.

Gallbladder Inflammation and Calcification

A history of antecedent chronic cholecystitis was present in 40% to 50% of patients with carcinoma of the gallbladder, which led to the incrimination of cholecystitis as an etiologic factor. This association is extremely difficult to evaluate, however. Calcification of the gallbladder itself, the so-called porcelain gallbladder, is a significant risk factor for gallbladder cancer, with an incidence ranging between 12.5% and 61% [13,14]. The risk of cancer in typhoid carriers is six times higher than that in the general population [15].

Benign Neoplasms

There is a very small risk, if any, for malignant degeneration of benign tumors of the gallbladder without associated cholelithiasis. Phillips [16] studied 500 papilloma cases and found one case of adenocarcinoma. Christensen and Ishak [17] found 3 of 29 nonpapillary adenomas to contain carcinoma in situ.

Chemical Carcinogens

TABLE 1

Symptoms and Signs of Gallbladder Carcinoma

Mancuso and Brennan [18] have reported both a higher incidence and earlier onset of gallbladder cancer in rubber industry workers than in controls. In animal models, chemical carcinogens, especially nitrosamines and methylcholanthrene, have been implicated in the etiology of gallbladder cancer [19].

Clinical Presentation

In its early stages, carcinoma of the gallbladder is usually asymptomatic. The lack of specific signs or symptoms prevents detection of this cancer at an early and resectable stage. Moreover, when symptoms do occur, they usually resem- ble those of benign gallbladder disease.

Common symptoms include abdominal pain, nausea, vomiting, weight loss, and anorexia ( Table 1). A changing pattern of the character of the pain is usually described. The median duration of symptoms varies from 1.8 months to 3 years [4,7,8]. Physical findings may include tenderness or a mass in the right upper abdominal quadrant, jaundice, cachexia, fever, and ascites.

Diagnosis

TABLE 2

Nevin Staging System for Gallbladder Cancer
TABLE 3

TNM Staging System for Gallbladder Cancer

Laboratory findings in patients with gallbladder carcinoma are nonspecific. Liver function abnormality is the most common lab finding in these patients. Serum alkaline phosphatase, direct bilirubin, and serum aspartate aminotransferase levels are elevated in 50% or more of cases. The typical patient is mildly hypoalbuminemic. Only 10% of patients have a hemoglobin level lower than 11 g/dL [20].

Ultrasonography is abnormal in 98% of patients (with findings including cholelithiasis, a thickened gallbladder, a mass in the gallbladder, or some combination) and is diagnostic for cancer in 22% of cases.20 In other review articles [7,8] none of 146 patients with gallbladder cancer was diagnosed prior to surgical exploration.

Impact of Advances in Imaging

To study the effect of recent advances in diagnosis and their impact on survival of patients with gallbladder cancer, Ouchi and colleagues [21] compared two groups of patients: Group I, who underwent resection between 1960 and 1978, and group II, who had surgery between 1979 and 1991. Preoperative diagnosis, including suspected carcinoma, was made in 42% of group I patients and 60% of group II. A definitive preoperative diagnosis of gallbladder carcinoma was made in 8% of group I and 36% of group II. The diagnostic accuracy of ultrasonography and CT scanning in the two groups was 36% and 70%, respectively.

In another study, CT was diagnostic in 6 of 12 patients (50%) [20]. Of 157 histologically proven positive nodes in 51 patients with gallbladder carcinoma, 60 (38%) were visualized at CT scanning [22].

In summary, preoperative diagnosis of gallbladder carcinoma is uncommon. Nevertheless, recent advances in biliary tract imaging have increased the diagnostic yield.

Staging

The first staging system for gallbladder carcinoma was developed by Nevin and coworkers in 1976 (Table 2) [23]. It is based on the level of tumor invasion. Recently, a TNM system was adopted (Table 3) [24]. Both systems correlate very well with prognosis [20,23,25].

Pages

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.